Transcode Therapeutics (RNAZ) Non-Current Assets (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Non-Current Assets came in at $140.4 million in Q1 2026, up 93518.71% YoY from N/an in Q1 2025, and little changed on a QoQ basis from $140.4 million in Q4 2025.
Transcode Therapeutics (RNAZ) Non-Current Assets (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Non-Current Assets data on file, last reported at $140.4 million in Q1 2026.
- Quarterly Non-Current Assets rose 93518.71% year-over-year to $140.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281.3 million (up 25180.66% YoY) and the FY2025 annual result came in at $140.4 million, up 69702.21% from the prior year.
- Non-Current Assets held at $140.4 million in Q1 2026, from $140.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $140.4 million in Q1 2026 to a low of $24689.0 in Q2 2025.
- A 5-year average of $16.9 million and a median of $445688.0 in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2025 — Non-Current Assets tumbled 94.37% — and 2026, when it soared 93518.71%.
- Tracing RNAZ's Non-Current Assets over 5 years: stood at $208581.0 in 2022, then jumped by 242.44% to $714257.0 in 2023, then tumbled by 71.84% to $201161.0 in 2024, then jumped by 69702.21% to $140.4 million in 2025, then rose by 0.0% to $140.4 million in 2026.
- The last three Non-Current Assets figures came in at $140.4 million (Q1 2026), $140.4 million (Q4 2025), and $475634.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 140.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 140.42 Mn |
| Dec 31, 2025 | 140.41 Mn |
| Sep 30, 2025 | 475,634.00 |
| Jun 30, 2025 | 24,689.00 |
| Mar 31, 2025 | 149,987.00 |
| Dec 31, 2024 | 201,161.00 |
| Sep 30, 2024 | 323,516.00 |
| Jun 30, 2024 | 438,167.00 |
| Mar 31, 2024 | 576,445.00 |
| Dec 31, 2023 | 714,257.00 |
| Sep 30, 2023 | 854,430.00 |
| Jun 30, 2023 | 988,608.00 |
| Mar 31, 2023 | 1.24 Mn |
| Dec 31, 2022 | 208,581.00 |
| Sep 30, 2022 | 445,688.00 |
| Jun 30, 2022 | 234,673.00 |
| Mar 31, 2022 | 215,324.00 |
| Dec 31, 2021 | 206,268.00 |
| Sep 30, 2021 | 155,610.00 |
| Jun 30, 2021 | 982,046.00 |